We analyse the case of Histocell, a biopharmaceutical company focused on the development of drugs and medical devices for regenerative medicine and cell therapy, from a corporate finance perspective. Firstly, we will explain the strategic rationale through the inauguration of its new production centre. Then, we will highlight the capital investment Histocell has received thanks to the Japanese investment fund Cell Innovation Partners, an operation that has made the opening of its new plant possible.

Get in touch with our experts.

We analyse the case of Histocell, a biopharmaceutical company focused on the development of drugs and medical devices for regenerative medicine and cell therapy, from a corporate finance perspective. Firstly, we will explain the strategic rationale through the inauguration of its new production centre. Then, we will highlight the capital investment Histocell has received thanks to the Japanese investment fund Cell Innovation Partners, an operation that has made the opening of its new plant possible.

Histocell inaugurates a plant dedicated to the manufacture of medical devices

La empresa biofarmacéutica vasca Histocell inauguró en Larrabetzu un nuevo centro productivo dedicado a la elaboración de productos sanitarios de medicina regenerativa.

Hostocell belongs to the NorayBio Group. This group was created in 2006 with the aim of bringing together innovative Basque biotech companies with an international vocation. The group, founded by Julio Font and Marta Acilu, currently includes three companies in the bioscience area located in the Science and Technology Park of Bizkaia: Noray Bioinformatics, Histocell and ArtinVet.

Histocell is a biopharmaceutical company that develops cell therapy and tissue engineering products for regenerative medicine. Histocell began its trajectory in the Department of Cell Biology and Histology of the Faculty of Medicine and Odontology of the University of the Basque Country, to later set up in 2005 in the Science and Technology Park of Bizkaia. However, the aim of this new centre is to house research, production and marketing activities for its Reoxcare line of treatment for difficult-to-heal wounds and its Wharton Gel Complex and Histoessence dermocosmetic products.

In short, the creation of this plant has involved an investment of €1.6m and will generate 10 jobs at the start of its operation and, it is expected, around 30 in the coming years. With all this, the company forecasts sales of €6m by 2021.

CORPORATE FINANCE EXPERTS

Capital increase for the start-up of the new production site thanks to the Japanese investment fund Cell Innovation Partners.

The inauguration is not the only business milestone achieved by Histocell this year. The company has also carried out a capital increase for the opening of its new plant in which the Japanese investment fund Cell Innovation Partners has entered. This fund is related to Histocell's activity, as it also specialises in regenerative medicine and cell therapy. The main partners of this fund are the Japanese company Reprocell and Shinsei Bank.

Por un lado, Reprocell se fundó en 2003 por investigadores universitarios japoneses. Tiempo después, se convirtió en la empresa líder en investigación de células madre en Japón. En los últimos años, se expandió a través de una serie de acquisitions convirtiéndose en Compañías del Grupo REPROCELL. De esta manera, cada empresa adquirida aporta propiedad intelectual y conocimiento que ayuda a amplificar el valor de la organización. Más recientemente, estas empresas se han integrado y consolidado en oficinas regionales, y los nombres se han convertido en marcas de productos y servicios.

On the other hand, Shinsei Banka Japanese financial institution offering a full range of financial products and services for institutional and individual clients. Shinsei combines its commercial and investment banking operations - with frequent investments in Europe - with an Institutional Banking division that engages in a wide range of commercial lending and equity investments. This division is affiliated with four subsidiary companies: Shinsei Investment Management, Shinsei Securities, Shinsei Servicer and Shinsei Trust and Banking.

Finally, Histocell has obtained the necessary investment to start up its new production centre in Larrabetzu, in which its partners and some institutional bodies such as the Provincial Council of Bizkaia and the Basque Government's Gauzatu programme, dedicated to promoting the creation and development of technology-based and innovative SMEs, have also participated.

Analysis of similar operations in the field of regenerative medicine

The following table lists five international operations related to regenerative medicine. For example, Humacyte offers human tissue-based products for regenerative medicine and vascular surgery applications. The company, which was incorporated in 2004 and is based in North Carolina, has received 467.9M$.

Other posts that may interest you

https://techma.bakertilly.es/analisis-inversion-en-el-sector-dental-tech-createch-medical-y-straumann/

https://techma.bakertilly.es/analisis-de-la-inversion-en-rv-en-salud/

https://techma.bakertilly.es/nokia-compra-la-empresa-de-gadgets-de-salud-withings-entra-en-el-mundo-e-health/

If you are looking for investors, you want to buy or sell your company or finance your R&D&I project, get in touch with our Corporate Finance experts.

If you are looking for investors, want to buy or sell your company or finance your R&D&I project, contact our Corporate Finance experts.